GPCRs are proteins found on the surface of all cells in the body that recognize and bind hor mones and neurotransmitters. Their principal purpose is to transmit a signal to active pro teins on the inside of the cell, thereby chang ing the cell's behaviour. There are more than 800 GPCRs in the human genome. They mediate the majority of the body's response to hormones and neurotransmitters, and are responsible for the senses of sight, smell and taste. GPCRs are involved in so many aspects of normal physiology, including homeostasis. It is interesting to understand how protein structures mediate signalling behaviours; understanding the structures may be helpful in developing more selective and effective drugs for these receptors, which represent approxi mately 30% of current drug targets. My initial interest in βadrenergic receptors came from my clinical experi ence using βagonists to treat asthma and βblockers to treat heart disease. 
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Young scientists meet laureates, in four films:
Why is the structure of GPCRs so hard to crack?
To determine the structure of proteins such as GPCRs it is necessary to crystalize the pro tein. The diffraction patterns of Xrays that pass through the crystals can then be used to determine the crystals' 3D structure. The first GPCR structure to be solved -rhodopsin, which is a protein in the rods of the retina that can respond to a single photon of light -was an incredible challenge. Even though rhodop sin is abundant and is one of the most bio chemically stable GPCRs, it has relatively little polar surface area, which makes it difficult to form crystals. Solving the structure of the βreceptor, a different GPCR that is activated by the hormone adrenaline, was even more challenging. Unlike rhodopsin, there is no tis sue in which the βreceptor is expressed at high levels so we had to use cultured cells to produce the receptor. The βreceptor is flexible and bio chemically unstable and it is difficult to obtain enough protein to allow crystallography trials.
Did you expect the project to be so tough?
No! When we set out in the early 1990s, we didn't know the first thing about crystallography or about the biochemical behaviour of these proteins, for example whether they were dynamic or unstable. Using a technique called fluorescence spectroscopy we were able to get structural information that provided insight into why it was so difficult to crystallize the βreceptors. We learned that the βreceptor did not operate as a simple two state on-off system, but that its shape was complex and flexible. For proteins to crys tallize they must all be in the same con formation -that is, they must all have the same shape -but our fluorescence studies suggested that the βreceptor did not exist in a single conformation even when bound to an antagonist or agonist. A population of recep tors in solution have different shapes -subtle differences, but sufficiently large to prevent crystal formation.
What breakthrough allowed you to determine the structure of the β 2 adrenergic receptor?
We finally obtained our first crystals in 2004, but they were too small to be analysed using conventional Xray sources. I showed pictures of the crystals to Gebhard Schertler, who at the time was helping to develop a microfocus Xray beamline at the European Synchro tron Radiation Facility (ESRF) in Grenoble, France. We saw the first diffraction patterns at the ESRF in July 2005, confirming that we had a protein crystal. The quality was too poor to determine the 3D structure but the result gave us hope that we could improve the quality of the crystals. My wife joined me for the first experiment at the ESRF that July, and she was the first to see a diffraction pattern, confirming that we had a protein crystal.
Until then I had felt that the project might fail, so I didn't think it was suitable for a student or postdoctoral researcher to work on. After wards I recruited two very talented postdocs to join the effort and they succeeded in determin ing structures of the β 2 adrenergic receptor in 2007 with the help of Stanford colleagues and collaborators from other universities.
How has your wife contributed to your success?
She has been extremely supportive and although she is not a trained biochemist she is very good at finding ways to make the research process more efficient. We met in our first biology class in college and we have worked together ever since, so she understands what I do and does not ask why I spend so much time in the lab.
Were you driven by fear of another group discovering the GPCR structure first?
I had always hoped that someone would get the result, but of course we wanted to be first.
We knew there were other groups working on similar projects and there were often rumours that one group or another had crystals. Even as recently as spring 2007, while we were working to obtain the final data for our two structures, there was a detailed rumour that a group in France had the β 2 structure and that a paper had been submitted. That turned out to be false, but it was fortunate for us because it prompted a friend at a Danish pharmaceutical company to donate US$100,000 to our project at a time when things were tight financially.
Did you ever imagine that you might win a Nobel, and what effect it would have?
The first time I really became aware of the prize was in the 1990s when I visited Stock holm while on vacation with my family. We visited the city hall where the ceremony is held and our tour guide described the ceremony. I thought about how exciting it would be, but it never occurred to me that I might win it until 2012, when I found out I' d been chosen. That first year was very disruptive, in part because I accepted too many invitations to speak at con ferences and visit universities, often overseas. The volume of email also increased dramati cally and as a result I wasn't spending enough time focusing on my research.
Will you continue working in this field?
Yes. There are plenty of challenges ahead in the GPCR field. A crystal structure only gives us a snapshot of the protein in a single state, but these proteins are in constant motion between different states. The role that dynamic behav iour plays in receptor function is of great interest to membraneprotein structural biologists, biochemists, pharmacologists and pharmaceuticalcompany scientists. There is a lot more work required before we understand how receptors signal to G proteins and other cellsignalling and regulatory proteins such as kinases and arrestins. We also know very little about how receptors work in their native envi ronment: the plasma membrane of living cells. Developing methods to study receptor struc ture and dynamics in living cells may be even more challenging than crystallographic stud ies. It will help us to understand the versatile signalling behaviour of GPCRs at a molecular level. By versatile, I mean that one receptor may signal through different intracellular signal ling proteins. A better understanding of this behaviour may help us to develop more effec tive drugs. ■ Haya Jamal Azouz is a medical student at Alfaisal University in Riyadh, Saudi Arabia, where she investigates novel approaches to cancer therapy. 
